Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer

Tumori

Volumn 97, Issue 3, 2011, Pages 286-289

  Ertan, Esra ^a   Soydinc, Hilal ^b   Yazar, Aziz ^c   Ustuner, Zeki ^d   Tas, Faruk ^b   Yasasever, Vildan ^b  

^a Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Matrix metalloproteinase 9; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; GELATINASE B; GEMCITABINE; NAVELBINE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; SMOKING; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 79960854209     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/912.10023     Document Type: Article

References (16)

1. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer, 68: 162-165, 1993. (Pubitemid 23178571)
2. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H: Expression ofmatrixmetalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int, 47: 461-469, 1997. (Pubitemid 27280170)
3. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res, 6: 2349-2355, 2000. (Pubitemid 30399202)
4. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffman C, Vohminkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol, 13: 1550-1557, 2002. (Pubitemid 35331452)
5. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, Görn M, Vohwinkel G, Edler L, Fiedler W, Hossfeld DK: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 50: 51-58, 2005. (Pubitemid 41297469)
6. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung, 183: 29-42, 2005. (Pubitemid 41264745)
7. Therasse P, Arbuck SG, Eisenhaver EA, Wanders J, Kaplan RS, Rubinstein L, Verwell J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SC: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92: 205-216, 2000. (Pubitemid 30099779)
8. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Coller MA, Shepheld FA: Phase III study of the matrix metalloproteinase inhibitor prinomastat in non-small cell lung cancer (NSCLC). J Clin Oncol, 23: 842-849, 2005. (Pubitemid 46224184)
9. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM: Expression ofmatrixmetalloproteinase 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer, 51: 313-321, 2006. (Pubitemid 43265814)
10. Yazar A, Soydinç H, Ertan E, Yasasever V, Tas F: The role of serumvascular endothelial growth factor andmatrixmetalloproteinase- 9 in predicting response to chemotherapy and prognosis in patients with advanced non-small cell lung carcinoma. South Med J, 101: 327-328, 2008. (Pubitemid 351499291)
11. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y: Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res, 30: 713-718, 2010
12. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Capelozzi VL: Prognostic relevance of TTf-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer, 64: 105-159, 2009.
13. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM: Tumor response to combination celecoxib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol, 3: 117-124, 2008. (Pubitemid 351323184)
14. Yoshimoto A, Kasahara K, Nishio M, Hourai T, Sone T, Kimura H, Fujimura M, Nakao S: Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. Jpn J Clin Oncol, 35: 233-238, 2005. (Pubitemid 41444287)
15. Hrabec E, Strek M, Nowak D, Hrabec Z: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med, 95: 1-4, 2001. (Pubitemid 32621978)
16. Koc M, Ediger D, Budak F, Karadag M, Oral HB, Uzaslan E, Ege E, Gozu RO:Matrixmetalloproteinase-9 (MMP) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori, 92: 149-154, 2006. (Pubitemid 43835975)